Semax (ACTH Fragment Peptide)

A Mechanism Layer Below Gene Expression

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Kolbaev and colleagues examined the effect of Semax on intracellular calcium dynamics in rat brain neurons, published in the Bulletin of Experimental Biology and Medicine in August 2025 — a different and faster level of mechanism than the neurotrophin expression literature.

Key facts

Study
Kolbaev 2025 (PMID 41171324)
Journal
Bull Exp Biol Med, August 2025
Preparation
Rat brain neurons
Measured
Intracellular calcium dynamics
Timescale
Seconds to minutes
Contrast
Gene expression acts over hours

Why calcium is a useful readout

Intracellular calcium concentration is one of the most general signalling variables a neuron has. It changes within seconds of a stimulus, it is measurable in living cells with fluorescent indicators, and it sits upstream of a great many downstream processes. A compound that alters calcium dynamics is doing something at the level of immediate cell signalling.

Why this differs from the neurotrophin work

The existing Semax literature centres on expression of neurotrophins such as BDNF and NGF — a transcriptional readout operating over hours. Calcium operates over seconds. These are not competing accounts; they are different levels of a potential causal chain, and a fast signalling event is the kind of thing that could sit upstream of a slower transcriptional one.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

Why a fast readout is analytically valuable

Expression changes measured hours after exposure leave a long interval in which many things could intervene. An effect appearing within seconds in isolated neurons is much harder to attribute to anything other than the compound present, which narrows the causal question considerably even without identifying a receptor.

What it does not establish

A receptor, or a behavioural consequence. Altered calcium dynamics in rat brain neurons is a cellular observation. Semax still has no identified receptor, and a calcium effect is compatible with several mechanisms including indirect ones. It narrows the question rather than answering it.

Where the publication sits

The Bulletin of Experimental Biology and Medicine is a Russian journal, and the Semax literature is substantially Russian in origin — a point the existing literature article on this site makes. That is context for interpretation rather than a dismissal: the language and location of publication are not measures of quality, and limited independent replication outside that tradition is a genuine and separate limitation.

Regulatory position

Semax holds no marketing authorisation from the MHRA, EMA or FDA. Registration in another jurisdiction does not alter that, and material supplied here is for laboratory research only with no claim about any effect in any person.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

  • Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
  • Neuroprotection and cerebral ischaemia models
  • Study of proline-stabilised peptide design
  • Comparative work on ACTH fragments without steroidogenic activity
  • Transcriptomic profiling in rodent brain models

Handling checklist

  • Store lyophilised material cold, dry and protected from light
  • Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
  • No reducing agent needed — the sequence contains no cysteine
  • Introduce diluent gently against the vial wall; swirl rather than shake
  • Aliquot to avoid repeated freeze-thaw cycles
  • Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Related questions researchers ask

  • What is Semax?
  • Is Semax really an ACTH(4-10) analogue?
  • How does Semax affect BDNF?
  • What are glyprolines?
  • Is Semax approved in the UK?
  • How does Semax differ from Selank?

Frequently asked questions

What did the 2025 study measure?
Intracellular calcium dynamics in rat brain neurons following Semax exposure — a cellular signalling readout.
How does that relate to the BDNF work?
Different timescales. Calcium changes within seconds; gene expression over hours. A fast event could sit upstream of a slower transcriptional one.
Does it identify a receptor?
No. Semax still has no identified receptor, and a calcium effect is compatible with several mechanisms including indirect ones.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

JM

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.